On Tuesday, Shares of PMC-Sierra Inc. (NASDAQ:PMCS), dropped -2.14% to $8.67.
PMC-Sierra, stated results for the first quarter ended March 28, 2015.
Net revenues in the first quarter of 2015 totaled $133.1 million, an enhance of 5 percent contrast to $126.5 million in the first quarter of 2014, and a decrease of 3 percent from $136.9 million in the fourth quarter of 2014. Storage product revenues in the first quarter of 2015 totaled $96.5 million, an enhance of 11 percent from $87.0 million in the first quarter of 2014.
GAAP net income in the first quarter of 2015 totaled $4.7 million or $0.02 per diluted share, contrast to GAAP net loss in the first quarter of 2014 of $4.2 million or $0.02 per share, and GAAP net income in the fourth quarter of 2014 of $2.3 million or $0.01 per diluted share.
Non-GAAP net income in the first quarter of 2015 totaled $20.9 million or $0.10 per diluted share, contrast to non-GAAP net income in the first quarter of 2014 of $16.0 million or $0.08 per diluted share, and to non-GAAP net income in the fourth quarter of 2014 of $22.7 million or $0.11 per diluted share.
PMC-Sierra, Inc. designs, develops, markets, and supports semiconductor solutions for communications network infrastructure equipment worldwide. Its semiconductor devices enable networking equipment primarily in three markets, counting storage, optical, and mobile networks.
Shares of H&R Block, Inc. (NYSE:HRB), declined -2.01% to $31.26, during its last trading session.
H&R Block, released its U.S. tax results through April 16, 2015. Total U.S. revenues raised contrast to the preceding year despite a 0.9% decrease in returns prepared to 20.5 million. The company continues to expect EBITDA margins of about 30%.
Total H&R Block U.S. assisted returns prepared fell 4.6% through April 16. The company believes this decline is due to the second-year impact of discontinued the company’s free federal 1040EZ promotion and the ongoing impact of industry-wide fraud, particularly related to behavioral shifts in tax filers who claim the EITC. Tax returns prepared through the company’s tax software products, counting online, desktop and mobile applications, raised 8.2%.
The Affordable Care Act (ACA) intersected with tax preparation for the first time in tax season 2015, requiring millions of taxpayers to file additional forms and in many cases resulting in modified refunds and tax penalties.
Additionally, fraud continued to negatively impact the tax industry as tax identity theft and improper EITC payments continue to cost taxpayers billions of dollars.
H&R Block, Inc., through its auxiliaries, provides tax preparation and related services to the general public primarily in the United States, Canada, and Australia.
At the end of Tuesday’s trade, Shares of Medivation, Inc. (NASDAQ:MDVN), dwindled -1.92% to $124.19.
Medivation, declared that it will host a live teleconference with administration to talk about first quarter 2015 financial results and provide a general business update on May 7, 2015 at 4:30 p.m. Eastern Time. A press release for the first quarter will be released after markets close on May 7, 2015.
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
Finally, INSYS Therapeutics, Inc. (NASDAQ:INSY), ended its last trade with -1.91% loss, and closed at $55.34.
Insys Therapeutics, declared that the Company will release its financial results for the first quarter 2015 on Thursday, May 7, 2015, before the U.S. financial markets open.
Following the release of the financial results, Michael L. Babich, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call.
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
